Company intelligence / Profile preview
EpiVax Therapeutics
Providence, Rhode Island, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
EpiVax Therapeutics is developing personalized neoantigen vaccines for cancer and a T cell epitope‑based peptide vaccine for COVID‑19; its COVID‑19 candidate EPV-CoV-19 has completed IND‑enabling preclinical studies with in vitro human T cell and in vivo HLA‑transgenic mouse immunogenicity data, and cancer programs are currently at preclinical and vaccine-design capacity stages.[4][5][6]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinePeptidesmRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GreenLight Biosciences[6]
Beyond the preview
Go deeper on EpiVax Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiVax Therapeutics.